scholarly journals Gestational diabetes and polycystic ovary syndrome

2014 ◽  
Author(s):  
Christiana Georgiou ◽  
Helen Mason ◽  
Gul Bano
Keyword(s):  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome

scholarly journals Pregnancy-related outcomes for women with polycystic ovary syndrome

2017 ◽  
Vol 13 (3) ◽  
pp. 89-97 ◽  
Author(s):  
Rose McDonnell ◽  
Roger J Hart
Keyword(s):  
Health Care ◽  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Congenital Anomalies ◽  
Polycystic Ovary ◽  
Reproductive Function ◽  
Short Term ◽  
Ovary Syndrome ◽  
Endocrine Disorder ◽  
Hypertensive Disorders

The polycystic ovary syndrome is a common endocrine disorder that has profound implications for women throughout their reproductive years. A diagnosis of polycystic ovary syndrome is associated with reproductive challenges including a difficulty in conceiving as well as the pregnancy-related complications of miscarriage, hypertensive disorders, gestational diabetes and prematurity. Consequently, polycystic ovary syndrome has profound implications for women and their offspring with regard to reproductive function in the short term and in the longer term the risk of chronic illness and congenital anomalies, and health care resources should be directed accordingly to mitigate against these risks.

Oral probiotics in women's health: experimental evidence and results from clinical trials

2021 ◽  
Vol 20 (2) ◽  
pp. 102-109
Author(s):  
E.V. Shikh ◽  
◽  
A.A. Makhova ◽  
S.S. Sharonova ◽  
◽  
...  
Keyword(s):  
Clinical Trials ◽  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Viral Infections ◽  
Polycystic Ovary ◽  
Gynecological Cancer ◽  
Ovary Syndrome ◽  
Treatment Regimens ◽  
Probiotic Lactobacilli

The review presents data from experimental research of the anti-inflammatory activity of Lactobacillus paracasei, L. plantarum, L. rhamnosus, the antitumor activity of L. rhamnosus GG and GR-1, L. gasseri, L. crispatus. The prospect of using probiotics in cancer treatment regimens with the aim to increase the tolerability of treatment was considered. The data confirming the ability of probiotic lactobacilli (L. reuteri and L. rhamnosus) to enhance barrier functions of endometrial epithelial cells in response to human papillomavirus-1 were presented. The perspectives of using microbiota modulation to prevent and/or protect the reproductive system against infection were discussed. The data of clinical trials using multi-strain probiotics containing Lactobacillus and Bifidobacterium in women with gestational diabetes were analyzed. A hypothesis on the role of microbiota in the pathogenesis of polycystic ovary syndrome (PCOS) was presented. Research results suggest that the use of probiotics can increase fertility in PCOS. Key words: viral infections, gestational diabetes mellitus, gynecological cancer, oral probiotics, polycystic ovary syndrome, Lactobacillus spp.

scholarly journals Risks for Gestational Diabetes Mellitus and Pregnancy-Induced Hypertension Are Increased in Polycystic Ovary Syndrome

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Yunhui Wang ◽  
Xiaomiao Zhao ◽  
Huidan Zhao ◽  
Hong Ding ◽  
Jianping Tan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Gestational Diabetes Mellitus ◽  
Ovarian Stimulation ◽  
Polycystic Ovary ◽  
Pregnancy Induced Hypertension ◽  
Ovary Syndrome ◽  
Induced Hypertension ◽  
Ivf Et

Objectives. To evaluate pregnancy outcomes and its determinants in women with polycystic ovary syndrome (PCOS).Methods. Two-hundred and twenty pregnant PCOS and 594 healthy women were followed from early pregnancy. Incidences of gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH), preterm birth, twinning, and fetal growth restriction (FGR) were determined.Results. The incidence of GDM was notably higher among all PCOS combined (54.9%; OR: 2.9, 95% CI: 2.0–4.1) and PCOS subgroups, whether they conceived spontaneously (51.5%; OR: 3.3, 95% CI: 2.0–5.4), or via IVF-ET or ovarian stimulation, compared with controls (14.3%;P<0.001). The incidence of PIH was also higher among all PCOS (10.4%; OR: 2.2, 95% CI: 1.1–4.4) and the subgroup conceiving spontaneously (11.8%; OR: 2.6, 95% CI: 1.1–6.2;P<0.001) but not for those conceiving with IVF-ET (9.1%) or ovarian stimulation (9.4%). Lean women with PCOS (BMI<24kg/m2) had higher incidences of GDM (51.1% versus 14.5%; OR: 5.6, 95% CI: 3.4–9.0) and PIH (8.9% versus 3.2%; OR: 3.0, 95% CI: 1.3–7.1) than lean controls. PCOS woemn with normal glucose tolerance had higher risk for PIH than their comparable control group (OR: 4.0, 95% CI: 1.3–11.7).Conclusion. This study suggested that PCOS is an independent risk factor for the development of GDM and PIH. This trial is registered withChiCTR-RCC-11001824.

scholarly journals Effect of Metformin Intervention during Pregnancy on the Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Zhihong Zhuo ◽  
Aiming Wang ◽  
Huimin Yu
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Gestational Diabetes Mellitus ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Fixed Effect Model ◽  
Ovary Syndrome ◽  
Insulin Sensitizer ◽  
Functional Consequences

Metformin is an effective insulin sensitizer treating type 2 diabetes mellitus. However, the functional consequences of metformin administration throughout pregnancy on gestational diabetes mellitus (GDM) with polycystic ovary syndrome (PCOS) have not been assessed. We therefore performed a meta-analysis and system review to determine the effect of metformin on GDM in PCOS. A meta-analysis was performed on the published studies before December, 2013. Meta-analysis examined whether metformin could reduce GDM occurrence in PCOS with a fixed effect model. The odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the strength of association. A total of 13 studies including 5 RCTs and 8 non-RCTs were enrolled. Ultimately, effectiveness analysis demonstrated that, in total, there was no significant availability of metformin on GDM in PCOS in contrast to placebo (OR = 1.07, 95% CI 0.60–1.92) in RCTs and significant availability of metformin on GDM (OR = 0.19, 95% CI 0.13–0.27) was indicated in non-RCTs. In summary, according to the results of our meta-analysis, strictly, metformin did not significantly effect on GDM with PCOS, though more multicenters RCTs still need to be investigated.

Sign in / Sign up

Export Citation Format

Share Document